美国用于自体免疫疾病的 IVD 和 LDT 市场规模、份额和趋势分析报告：按类型、技术、应用、国家、细分市场预测，2024-2030 年

美国自体免疫疾病 IVD 与 LDT 市场成长及趋势：

Grand View Research, Inc.的最新报告显示，美国自体免疫疾病IVD和LDT市场预计2024年至2030年复合年增长率为4.8%，到2030年将达到37亿美元。

自体免疫疾病的高盛行率、对这些疾病的认识不断提高、对技术开发和高性能产品的需求不断增加以及对研究的高投资是推动市场成长的因素。

这些健康问题是美国慢性病的第二大原因，也是美国女性死亡的主要原因之一。这些疾病对患者的劳动生产力和生活品质产生负面影响，并造成经济负担，对美国的医疗费用支出重大影响。美国国立卫生美国估计，与这些疾病相关的直接医疗费用约为 1,000 亿美元，其中癌症医疗费用达到 570 亿美元。

在美国，受这些疾病影响的人数众多，其盛行率以惊人的速度上升，导致医疗费用增加，这些都是优先事项，因此预计将推动成长。此外，此类健康疾病导致的併发症，如内臟器官损伤、运动能力下降和死亡风险，使得此类疾病的早期诊断和介入极为重要。人们对这种情况的认识不断提高预计将推动市场成长。

许多研究人员认为，全球自体免疫疾病的增加是由于遗传倾向和环境因素造成的。然而，人们对于环境中什么因素引发自体免疫疾病的了解却甚少。

儘管FDA将体外诊断作为医疗设备进行监管，但过去并无权监管LDT。随后，FDA宣布将利用医疗设备监管权限对LDT进行监管。一些研究人员认为 FDA 对 LDT 的监管将增加测试开发的时间和成本。

美国自体免疫疾病 IVD 和 LDT 市场报告亮点

• 2023年，类风湿性关节炎IVD将成为主要细分市场，收益占有率12.14%，类风湿性关节炎LDT份额为11.47%。类风湿性关节炎的高盛行率以及大量可用的诊断测试促进了市场占有率的成长。
• 2023年，临床化学成为领先细分领域，IVD市占率为32.37%，LDT市占率为19.98%。血液中自体抗体的诊断是最常见的诊断方法，因此占有很大的市场份额。
• 预计克隆氏症在预测期内将以最快的复合年增长率增长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国自体免疫疾病 IVD 和 LDT 市场变数、趋势和范围

• 市场介绍/系统展望
• 市场规模及成长前景
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 美国自体免疫疾病IVD和LDT市场分析工具
  • 波特的分析
  • PESTEL分析

第四章美国自体免疫疾病IVD和LDT市场：按类型估计和趋势分析

• 细分仪表板
• 美国自体免疫疾病 IVD 和 LDT 市场：2023 年和 2030 年按类型变化分析
• 体外诊断
• LDDT

第五章美国自体免疫疾病IVD和LDT市场：技术估算和趋势分析

• 细分仪表板
• 美国自体免疫疾病 IVD 和 LDT 市场：2023 年和 2030 年技术变化分析
• 免疫检测
• 临床化学
• 血液学
• 凝固
• 微生物学
• 分子诊断
• 其他的

第六章美国自体免疫疾病IVD和LDT市场：按应用估算和趋势分析

• 细分仪表板
• 美国自体免疫疾病 IVD 和 LDT 市场：2023 年和 2030 年按应用分类的变化分析
• 爱迪生氏症
• 僵直性脊椎炎
• 脱髮症
• 类风湿性关节炎
• 全身性红斑性狼疮
• 系统性硬皮症
• 干癣
• 抗磷脂抗体症候群
• 1型糖尿病
• 克隆氏症
• 溃疡性大肠炎
• 发作性睡病
• 多发性硬化症
• 葡萄膜炎

第七章 竞争格局

• 主要市场参与企业的最新趋势和影响分析
• 公司分类
• 企业热力图分析
• 公司简介
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux, Inc.
  • Corgenix, Inc.
  • Johnson &Johnson Services, Inc.
  • Microbix Biosystems Inc.
  • PerkinElmer, Inc.
  • SQI Diagnostics Inc.
  • Thermo Fisher Scientific Inc.

U.S. IVD And LDT For Autoimmune Diseases Market Growth & Trends:

The U.S. IVD and LDT for autoimmune diseases market size is expected to reach USD 3.70 billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.

U.S. IVD And LDT For Autoimmune Diseases Market Report Highlights:

• In 2023, the IVD for rheumatoid arthritis was the leading segment with a revenue share of 12.14% and the LDT for rheumatoid arthritis had a share of 11.47%. The large number of diagnostic tests available for it as well as the high prevalence of the disease contributed to the market share.
• In 2023, clinical chemistry was the leading segment with a market share of 32.37% in the IVD and 19.98% in the LDT. The diagnosis of autoantibodies in the blood is the most commonly employed diagnosis, thus contributing to the large share.
• Crohn's disease is projected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. IVD & LDT for Autoimmune Diseases Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Billion)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. U.S. IVD & LDT for Autoimmune Diseases Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. IVD & LDT for Autoimmune Diseases Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. IVD & LDT for Autoimmune Diseases Market: Type Movement Analysis, 2023 & 2030 (USD Billion)
• 4.3. IVD
  • 4.3.1. IVD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.4. LDT
  • 4.4.1. LDT Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
• 5.3. Immunoassays
  • 5.3.1. Immunoassays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Clinical Chemistry
  • 5.4.1. Clinical Chemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. Hematology
  • 5.5.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. Coagulation
  • 5.6.1. Coagulation Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Microbiology
  • 5.7.1. Microbiology Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. Molecular Diagnostics
  • 5.8.1. Molecular Diagnostics Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.9. Other
  • 5.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. IVD & LDT for Autoimmune Diseases Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. IVD & LDT for Autoimmune Diseases Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
• 6.3. Addison's Disease
  • 6.3.1. Addison's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Ankylosing Spondylitis
  • 6.4.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Alopecia Areata
  • 6.5.1. Alopecia Areata Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.6. Rheumatoid Arthritis
  • 6.6.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.7. Systemic Lupus Erythematosus
  • 6.7.1. Systemic Lupus Erythematosus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.8. Systemic Sclerosis
  • 6.8.1. Systemic Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.9. Psoriasis
  • 6.9.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.10. Antiphospholipid Antibody Syndrome
  • 6.10.1. Antiphospholipid Antibody Syndrome Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.11. Diabetes Type 1
  • 6.11.1. Diabetes Type 1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.12. Crohn's Disease
  • 6.12.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.13. Ulcerative Colitis
  • 6.13.1. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.14. Narcolepsy
  • 6.14.1. Narcolepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.15. Multiple Sclerosis
  • 6.15.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.16. Uveitis
  • 6.16.1. Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. Adaptive Biotechnologies Corporation
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments/ Strategic Initiatives
  • 7.4.2. Agilent Technologies Inc.
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments/ Strategic Initiatives
  • 7.4.3. Bio-Rad Laboratories, Inc.
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments/ Strategic Initiatives
  • 7.4.4. bioMerieux, Inc.
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments/ Strategic Initiatives
  • 7.4.5. Corgenix, Inc.
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments/ Strategic Initiatives
  • 7.4.6. Johnson & Johnson Services, Inc.
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments/ Strategic Initiatives
  • 7.4.7. Microbix Biosystems Inc.
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments/ Strategic Initiatives
  • 7.4.8. PerkinElmer, Inc.
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments/ Strategic Initiatives
  • 7.4.9. SQI Diagnostics Inc.
    • 7.4.9.1. Participant's Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Recent Developments/ Strategic Initiatives
  • 7.4.10. Thermo Fisher Scientific Inc.
    • 7.4.10.1. Participant's Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Recent Developments/ Strategic Initiatives